Expert Interview
Discussing the open label extension results of seralutinib from Gossamer Bio in treating Pulmonary Arterial Hypertension (PAH)
Ticker(s): GOSSInstitution: UCLA
- Professor of Medicine, David Geffen School of Medicine at UCLA, Chief of Cardiology and Director of the Pulmonary Hypertension Center Harbor-UCLA Medical Center.
- Manages 200 patients with Pulmonary Arterial Hypertension (PAH).
- Research focus has been to describe the physiologic abnormalities that are caused by PH using measurements of lung gas exchange during exercise, and to study exercise rehabilitation as a treatment modality for patients with pulmonary hypertension.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
